Cash Dwindles to $1.5M for Indaptus Therapeutics, Warns of Financing Uncertainty
INDP sits 16% above its 52-week low of $1.51 on light trading volume (0.1× avg).
Summary
Indaptus Therapeutics reported first-quarter 2026 financial results, revealing a critically low cash position of approximately $1.5 million as of March 31, 2026, down significantly from $8.5 million at year-end 2025. The company burned approximately $7.0 million in cash from operating activities during the quarter and explicitly stated it will need to raise additional capital, with no assurance that such financing will be available on acceptable terms or at all. This dire update follows the company's previous 10-K filing which included a going concern warning and significant shareholder dilution. The report also noted recent executive management changes and an ongoing review of development programs and resource allocation, signaling significant operational uncertainty. This rapid cash depletion and explicit financing warning indicate severe liquidity issues, making the company's viability highly questionable and requiring immediate attention from traders.
At the time of this announcement, INDP was trading at $1.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $1.51 to $19.91. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.